Detall

Activitat formativa del programa de doctorat Química Analítica i Medi Ambient
Dr. Norberto A. Guzman (Princeton Biochemicals, Inc., Princeton, New Jersey, U.S.A.)

Significant interest has evolved on the gut microbiota in recent years within the scientific community. The gut microbiota have been associated with a large array of human diseases ranging from luminal diseases such as inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), metabolic diseases such obesity and diabetes, allergic diseases to neurodevelopmental illnesses, though the strength of evidence is not robust with many of them. The normal gut microbiota imparts specific function in host nutrient metabolism, xenobiotic and drug metabolism, maintenance of structural integrity of the gut mucosal barrier, immunomodulation, and protection against pathogens. Diet is one of the most important modifying factors of the microbiota-gut-brain axis.
The gut is home to a diverse array of trillions of microbes, mainly bacteria, but also archaea, yeasts, helminth parasites, viruses, and protozoa. The gut microbiota is enriched with an efficient protein metabolizing machinery that function via the microbial proteinases and peptidases in tandem with human proteinases.

The purpose of this seminar is to describe the roles and functions of proline-rich nondegraded peptides derived from food, such as gluten-derived gliadin(s) and caseinderived casomorphin(s), in gastrointestinal diseases and mental disorders. In healthy states, food-derived opioid peptides could benefit both the nervous and digestive systems, whereas in pathological conditions, the gastrointestinal permeability change and an excess of opioid peptides may contribute to pathogenesis of some disorders. Immunoaffinity capillary electrophoresis will be described as a preferred technology to differentiate several structurally related opioid peptides.

References:

1. Atlas of Science – Another View of Science March 21 (2016), Guzman NA, Guzman DE.
2. Journal of Chromatography B, 1021: 14-29 (2016), Guzman NA, Guzman DE.
3. Archives of Biomedical Research, 1: 1-12 (2018), Guzman NA, Guzman DE.
4. U.S. Patent Number D857,231. Guzman NA, Guzman DE. Analyte Concentrator-Microreactor Device. Granted Date: August 20 (2019).
5. U.S. Patent Number 10,408,789. Guzman NA. Disease Detection System and Method. Granted Date: September 10 (2019).